Evaluation of Dextenza in Patients With Ocular Graft Vs Host Disease (GVHD) and Effect on Ocular Surface Disease Outcomes.
Latest Information Update: 07 Jan 2022
At a glance
- Drugs Dexamethasone (Primary)
- Indications Graft-versus-host disease; Ocular inflammation
- Focus Therapeutic Use
- 14 Dec 2021 Planned End Date changed from 1 Aug 2022 to 13 Dec 2021.
- 14 Dec 2021 Planned primary completion date changed from 1 Feb 2022 to 13 Dec 2021.
- 14 Dec 2021 Status changed from recruiting to discontinued. Reason the study was stopped: Due to difficulty enrolling subjects whom had not meet the inclusion criteria